Patents by Inventor Stefaan De Koker
Stefaan De Koker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240050574Abstract: The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.Type: ApplicationFiled: December 23, 2021Publication date: February 15, 2024Applicants: eTheRNA immunotherapies NV, Universiteit GentInventors: Stefaan DE KOKER, Bruno DE GEEST, Chen YONG
-
Publication number: 20240016738Abstract: The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.Type: ApplicationFiled: May 11, 2023Publication date: January 18, 2024Applicants: ETHERNA IMMUNOTHERAPIES NV, Vrije Universiteit BrusselInventors: Stefaan DE KOKER, Sanne BEVERS, Peter TOMME
-
Patent number: 11684577Abstract: The present invention relates to the field of lipid nanoparticles (LPN); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.Type: GrantFiled: January 18, 2019Date of Patent: June 27, 2023Assignees: ETHERNA IMMUNOTHERAPIES NV, Vrije Unversiteit BrusselInventors: Stefaan De Koker, Sanne Bevers, Peter Tomme
-
Publication number: 20230067722Abstract: The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionizable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in comprising less than about 1 mol % of a C18-PEG2000 lipid. The present invention provides use of the LNP's for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.Type: ApplicationFiled: January 21, 2021Publication date: March 2, 2023Inventors: Stefaan DE KOKER, Sanne BEVERS, Raymond Michael SCHIFFELERS, Sander Alexander Antonius KOOIJMANS
-
Publication number: 20220362360Abstract: The present invention relates to the field of mRNA formulations, and in particular provides a combination of one or more mRNA molecules encoding the functional immunostimulatory proteins CD40L, CD70 and caTLR4; and one or more mRNA molecules encoding an antigen. The combinations of the present invention are in particular characterized in that the mRNA molecules comprise a 5? CAP-1 structure and may further contain one or more modified nucleosides, such as pseudouridines. The present invention also provides compositions comprising said combinations and uses thereof, in particular in vaccination, and treatment of cell proliferative disorders.Type: ApplicationFiled: April 24, 2020Publication date: November 17, 2022Inventors: Stefaan De Koker, Sanne Bevers, Peter Tomme
-
Publication number: 20220143161Abstract: The present invention in general relates to a combination of mRNA molecules encoding functional immunostimulatory proteins and a CTLA4 pathway inhibitor. In particular, it relates to a combination of one or more mRNA molecules encoding at least one functional immunostimulatory protein selected from the list comprising: CD40L, CD70 and caTLR4; and a CTLA4 pathway inhibitor, optionally also in the form of an mRNA molecule. The present invention further relates to vaccines comprising such combination, as well as uses of the combinations and vaccine of the present invention in human or veterinary medicine, in particular in the prevention and/or treatment of cell proliferative disorders.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Inventors: Stefaan De Koker, Lukasz Bialkowski
-
Publication number: 20210386843Abstract: The present invention in general relates to a combination of mRNA molecules encoding functional immunostimulatory proteins and a PD-1 pathway inhibitor. In particular, it relates to a combination of one or more mRNA molecules encoding at least one functional immunostimulatory protein selected from the list comprising: CD40L, CD70 and caTLR4; and a PD-1 pathway inhibitor, optionally also in the form of an mRNA molecule. The present invention further relates to vaccines comprising such combination, as well as uses of the combinations and vaccine of the present invention in human or veterinary medicine, in particular in the prevention and/or treatment of cell proliferative disorders.Type: ApplicationFiled: January 3, 2020Publication date: December 16, 2021Inventors: Stefaan De Koker, Lukasz Bialkowski
-
Publication number: 20210121522Abstract: The invention relates to the field of immuno-oncology. More in particular, it relates to applying the mixed-lineage kinase domain-like protein (MLKL) or variants thereof in immunotherapeutic treatment of cancer. The MLKL or variant thereof is inducing an adaptive immune response to cancer cells leading to treatment of primary tumors and preventing development of secondary tumor or tumor metastasis.Type: ApplicationFiled: September 7, 2018Publication date: April 29, 2021Inventors: Xavier Saelens, Lien Van Hoecke, Stefaan De Koker, Johan Grooten
-
Publication number: 20200345641Abstract: The present invention relates to the field of lipid nanoparticles more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.Type: ApplicationFiled: January 18, 2019Publication date: November 5, 2020Applicant: ETHERNA IMMUNOTHERAPIES NVInventors: Stefaan DE KOKER, Sanne BEVERS, Peter TOMME
-
Publication number: 20130149357Abstract: The present invention discloses a composition comprising a polyelectrolyte complex and a polyol, characterised in that said polyol is in amorphous form. Optionally, the composition further comprises one or more drugs, wherein each drug has a molecular weight of at least 1000 Dalton. Said compositions are obtainable by spray-drying. The compositions may be prepared in particle form and as a suspension of particles. Pharmaceutical compositions are also provided for use in extracellular drug delivery. Pharmaceutical compositions are also provided that exhibit a controlled dual drug release.Type: ApplicationFiled: August 24, 2011Publication date: June 13, 2013Inventors: Jean Paul Remon, Bruno De Geest, Stefaan De Koker, Johan Grooten, Chris Vervaet